The question comes up every time a new product moves from the bench to a shipping lane. A process development team hands cold chain a molecule and a stability spec, and someone has to decide what keeps it cold in transit. The default answer is usually "whatever we used last time." That is how a stable protein ends up shipped in liquid nitrogen it never needed, and how a viable cell therapy ends up on dry ice that was never cold enough.
These three media are not a quality ladder where colder is better. They are three different tools with three different jobs. Choosing well saves money on the products that do not need extreme cold and prevents disasters on the ones that do. Here is the framework we walk Northeast biotech clients through.
The three media, by the numbers
Dry ice (solid CO₂). Holds a stable −78.5 °C as it sublimates from solid straight to gas. No liquid phase, no wet residue. It is a Class 9 dangerous good by air (UN 1845) but simple to handle on the ground. Widely available, low cost per pound, and the workhorse of frozen biologics shipping. The temperature is fixed by physics: you get −78.5 °C, not colder, not warmer, for as long as the ice lasts.
Liquid nitrogen (LN2). Holds −196 °C as a liquid, or roughly −150 °C and below in the vapor phase of a dry shipper. This is the only one of the three that protects the deep-frozen state that living cells require. It demands specialized dewars or vapor shippers, careful handling, and its own set of safety controls. Cost and complexity are the highest of the three.
Phase-change material (PCM). Engineered gels or salts formulated to hold a specific set point,some common examples being +5 °C, −20 °C, and points in between, by melting or freezing at that temperature. PCM does not go as cold as dry ice or LN2. Its value is precision and stability at a controlled band, and it is reusable. It is the right tool for refrigerated and chilled products, not deep-frozen ones.
The one variable that decides most of it
Start with the product's required storage temperature, because it eliminates options immediately.
If the molecule is stable at refrigerated (2 to 8 °C) or controlled ambient (15 to 25 °C), you are in PCM territory. Dry ice would freeze and likely destroy it. LN2 is absurd overkill. Most monoclonal antibodies in final formulation, many vaccines, and a large share of diagnostic reagents live here.
If the molecule needs a frozen state around −20 °C to −80 °C, dry ice is the standard answer. That band covers most bulk drug substance, mRNA, plasmids, DNA, protein reference standards, and a great deal of clinical trial material. Dry ice sits at −78.5 °C, comfortably inside the −70 °C-class frozen range these products are commonly stored at.
If the molecule contains viable cells that must stay below roughly −130 °C to remain below the glass transition temperature of water, only LN2 will do. Cell therapies, gene-modified cells, stem cells, and cryopreserved cell banks belong here. Dry ice at −78.5 °C is not cold enough and will cause ice recrystallization that kills cells. This is the single most expensive mistake in the category, and it is entirely avoidable by reading the stability spec.
The four-variable matrix
Once temperature narrows the field, four more variables settle the choice.
1. Required temperature. As above. Refrigerated to chilled: PCM. Frozen −20 to −80: dry ice. Deep cryogenic below −130: LN2.
2. Transit time and lane risk. Dry ice sublimates and eventually runs out, so it suits transits measured in hours to a few days with a known pack-out. LN2 dry shippers hold cryogenic temperature for ten days or more, which is why they anchor long international cell therapy lanes. PCM holds its set point until the material fully phase-changes, then drifts, so it wants a validated duration and a controlled ambient.
3. Handling and regulatory load. Dry ice is the easiest to source and handle but is a dangerous good by air. LN2 requires trained handlers, dewars, oxygen monitoring in the fill area, and its own dangerous goods classification. PCM is the simplest to handle and not a dangerous good, but conditioning it to the right temperature before packing is a step teams skip and regret.
4. Cost and reusability. Dry ice is low cost per shipment but consumable, so it recurs. PCM has a higher upfront cost per pack but is reusable across many shipments, which favors it on high-frequency chilled lanes. LN2 dry shippers are a capital and logistics investment justified only when the product genuinely requires cryogenic transport.
Where teams get it wrong
Shipping stable product cold. The most common waste. A protein stable at −20 °C gets shipped on dry ice at −78.5 °C because that is the standard box. It survives, so nobody questions it, and the organization pays for colder transport than the molecule needs, shipment after shipment. If the stability data supports a warmer medium, use it.
Shipping cells on dry ice. The most damaging error. Viable cells in DMSO put on dry ice arrive dead, and the temperature log often reads fine the whole way because −78.5 °C is exactly what the pack-out was designed to hold. It was the wrong target. Cells need LN2. Always check whether the payload is viable-cell material before defaulting to dry ice.
Treating PCM like an ice pack. PCM only works if it is pre-conditioned to its phase-change temperature before packing. Throwing an unconditioned pack in a box and hoping is how a chilled shipment arrives warm. The conditioning step is not optional.
Mixing media without validating the interaction. Dry ice inside a box that also carries PCM can freeze the PCM out of its working range and freeze product that was supposed to stay chilled. Combining media requires a validated configuration, not improvisation.
A quick reference
If the product needs... | Use | Why |
|---|---|---|
2 to 8 °C or controlled ambient | Phase-change material | Precise set point, reusable, not a dangerous good |
−20 to −80 °C frozen | Dry ice | Holds −78.5 °C, low cost, easy ground handling |
Below −130 °C, viable cells | Liquid nitrogen | Only medium that preserves the deep-frozen state |
Long international transit, frozen | Dry ice (short) or LN2 dry shipper (cryo) | Match hold time to lane length |
High-frequency chilled lane | Phase-change material | Reusable economics win over volume |
The role dry ice plays best
For the large middle of the biologics world, the frozen −20 to −80 °C band, dry ice is the correct and economical answer. It is available, it is simple to handle on the ground, and it holds the exact temperature most frozen biologics require. The engineering that matters is not choosing something colder. It is sizing the charge to the lane, using a validated shipper, and documenting the fill weight so the pack-out is repeatable. That is where a technical supplier earns its place: consistent pellet or slab quality, documented density, and delivery reliability that lets you validate a pack-out and trust it.
Questions we get asked
Can dry ice ever substitute for liquid nitrogen? Not for viable cells. −78.5 °C is far above the roughly −130 °C threshold cells need. For non-viable frozen material, dry ice is often the better and cheaper choice.
Is phase-change material colder than dry ice? No. PCM is formulated for specific set points warmer than dry ice, typically from +5 °C down to around −20 °C. Its advantage is precision and reusability, not extreme cold.
What holds temperature longest for a frozen shipment? For deep-frozen international lanes, an LN2 dry shipper holds cryogenic temperature ten days or more. For −70 °C-class frozen product over a few days, a well-sized dry ice pack-out in a validated shipper is standard.
How do I size the dry ice charge? By the container's sublimation rate, the transit time, and the payload, not by habit. A validated pack-out with a documented fill weight is the goal.
The summary, on one line
Match the medium to the molecule: PCM for chilled, dry ice for −20 to −80 °C frozen, LN2 for viable cells below −130 °C. Colder is not better, it is just more expensive, and for the frozen middle, dry ice is the right tool.
Cryo Life Solutions supplies pelletized and slab dry ice for biotech, pharma, and cell therapy support cold chain across the Northeast US. We provide consistent, documented product for validated pack-outs, and operate under documented GMP-aligned procedures while working toward full GMP certification. Standing orders and delivery available across MA, NH, RI, CT, NY, NJ, and PA. Call 603-802-6650 or email info@cryolifesolutions.com.
Related reading: Dry Ice for Biotech and Pharma Cold Chain: A Working Guide for Northeast US Operators
